Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It treats acute coronary syndrome and myocardial infarction, helping to prevent further thrombotic events in at‑risk patients.

GNH USA supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kogavant, a P2Y12 receptor antagonist, is employed in the management of coronary artery disease and related thrombotic conditions. - Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - ST‑elevation myocardial infarction (STEMI): provides rapid antiplatelet effect to limit clot propagation. - Non‑ST‑elevation myocardial infarction (NSTEMI): supports early reperfusion and secondary prevention. - History of myocardial infarction: lowers the incidence of recurrent thrombotic events.

Common Side Effects: - Dyspnea: shortness of breath, often mild to moderate. - Bleeding: including bruising, nosebleeds, or gastrointestinal bleeding. - Headache: transient and usually self‑limiting. - Nausea: occasional upset stomach. - Dizziness: may occur upon standing. - Hypotension: mild drops in blood pressure.

Serious or Rare Side Effects: - Severe or uncontrolled bleeding: intracranial or fatal hemorrhage. - Myocardial infarction recurrence: despite therapy. - Hepatic injury: elevated liver enzymes or hepatitis. - Thrombocytopenia: marked reduction in platelet count. - Allergic reactions: rash, angioedema, anaphylaxis. - Cardiac arrhythmias: ventricular or atrial rhythm disturbances.

Before initiating Kogavant, clinicians should consider the following precautions: - Assess bleeding risk: evaluate history of hemorrhage or anticoagulant use. - Monitor liver function: check hepatic enzymes periodically. - Evaluate renal function: adjust therapy in severe impairment. - Avoid in active pathological bleeding: discontinue if bleeding becomes uncontrolled. - Use caution in elderly patients: increased susceptibility to adverse events. - Store at room temperature: keep in the original pack, protect from moisture.

Kogavant may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ticagrelor exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy. - Concomitant anticoagulants (e.g., warfarin, heparin): heighten bleeding risk. Moderate Interactions (Monitor Closely): - NSAIDs: additive bleeding potential. - SSRIs or SNRIs: may increase hemorrhagic events. - Oral contraceptives: possible pharmacokinetic interaction. - Statins (especially high‑dose): modest increase in plasma levels. - Digoxin: potential for increased concentration.